Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer
- 11 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 17 (4), 341-347
- https://doi.org/10.1007/s10147-011-0298-z
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?Journal of Clinical Oncology, 2011
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08Journal of Clinical Oncology, 2011
- Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized studyInternational Journal of Clinical Oncology, 2010
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005
- Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancerAnnals Of Oncology, 2004
- Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium InfusionsClinical Cancer Research, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rateEuropean Journal Of Cancer, 1993